Constraining the brachial plexus does not compromise regional control in oropharyngeal carcinoma

Mutter W. Robert, Benjamin H. Lok, Pinaki R. Dutta, Nadeem Riaz, Jeremy Setton, Sean L. Berry, Anuj Goenka, Zhigang Zhang, Shyam Rao, Suzanne L. Wolden, Nancy Y. Lee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Accumulating evidence suggests that brachial plexopathy following head and neck cancer radiotherapy may be underreported and that this toxicity is associated with a dose-response. Our purpose was to determine whether the dose to the brachial plexus (BP) can be constrained, without compromising regional control.Methods: The radiation plans of 324 patients with oropharyngeal carcinoma (OPC) treated with intensity-modulated radiation therapy (IMRT) were reviewed. We identified 42 patients (13%) with gross nodal disease <1 cm from the BP. Normal tissue constraints included a maximum dose of 66 Gy and a D05 of 60 Gy for the BP. These criteria took precedence over planning target volume (PTV) coverage of nodal disease near the BP.Results: There was only one regional failure in the vicinity of the BP, salvaged with neck dissection (ND) and regional re-irradiation. There have been no reported episodes of brachial plexopathy to date.Conclusions: In combined-modality therapy, including ND as salvage, regional control did not appear to be compromised by constraining the dose to the BP. This approach may improve the therapeutic ratio by reducing the long-term risk of brachial plexopathy.

Original languageEnglish (US)
Article number173
JournalRadiation Oncology
Volume8
Issue number1
DOIs
StatePublished - Jul 9 2013
Externally publishedYes

Fingerprint

Brachial Plexus Neuropathies
Brachial Plexus
Carcinoma
Neck Dissection
Radiotherapy
Combined Modality Therapy
Head and Neck Neoplasms
Radiation

Keywords

  • Brachial plexopathy
  • Cetuximab
  • Cisplatin
  • Intensity-modulated radiation therapy
  • Oropharyngeal carcinoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Robert, M. W., Lok, B. H., Dutta, P. R., Riaz, N., Setton, J., Berry, S. L., ... Lee, N. Y. (2013). Constraining the brachial plexus does not compromise regional control in oropharyngeal carcinoma. Radiation Oncology, 8(1), [173]. https://doi.org/10.1186/1748-717X-8-173

Constraining the brachial plexus does not compromise regional control in oropharyngeal carcinoma. / Robert, Mutter W.; Lok, Benjamin H.; Dutta, Pinaki R.; Riaz, Nadeem; Setton, Jeremy; Berry, Sean L.; Goenka, Anuj; Zhang, Zhigang; Rao, Shyam; Wolden, Suzanne L.; Lee, Nancy Y.

In: Radiation Oncology, Vol. 8, No. 1, 173, 09.07.2013.

Research output: Contribution to journalArticle

Robert, MW, Lok, BH, Dutta, PR, Riaz, N, Setton, J, Berry, SL, Goenka, A, Zhang, Z, Rao, S, Wolden, SL & Lee, NY 2013, 'Constraining the brachial plexus does not compromise regional control in oropharyngeal carcinoma', Radiation Oncology, vol. 8, no. 1, 173. https://doi.org/10.1186/1748-717X-8-173
Robert, Mutter W. ; Lok, Benjamin H. ; Dutta, Pinaki R. ; Riaz, Nadeem ; Setton, Jeremy ; Berry, Sean L. ; Goenka, Anuj ; Zhang, Zhigang ; Rao, Shyam ; Wolden, Suzanne L. ; Lee, Nancy Y. / Constraining the brachial plexus does not compromise regional control in oropharyngeal carcinoma. In: Radiation Oncology. 2013 ; Vol. 8, No. 1.
@article{e65a63c0c106476ea3ee650881bf3dd8,
title = "Constraining the brachial plexus does not compromise regional control in oropharyngeal carcinoma",
abstract = "Background: Accumulating evidence suggests that brachial plexopathy following head and neck cancer radiotherapy may be underreported and that this toxicity is associated with a dose-response. Our purpose was to determine whether the dose to the brachial plexus (BP) can be constrained, without compromising regional control.Methods: The radiation plans of 324 patients with oropharyngeal carcinoma (OPC) treated with intensity-modulated radiation therapy (IMRT) were reviewed. We identified 42 patients (13{\%}) with gross nodal disease <1 cm from the BP. Normal tissue constraints included a maximum dose of 66 Gy and a D05 of 60 Gy for the BP. These criteria took precedence over planning target volume (PTV) coverage of nodal disease near the BP.Results: There was only one regional failure in the vicinity of the BP, salvaged with neck dissection (ND) and regional re-irradiation. There have been no reported episodes of brachial plexopathy to date.Conclusions: In combined-modality therapy, including ND as salvage, regional control did not appear to be compromised by constraining the dose to the BP. This approach may improve the therapeutic ratio by reducing the long-term risk of brachial plexopathy.",
keywords = "Brachial plexopathy, Cetuximab, Cisplatin, Intensity-modulated radiation therapy, Oropharyngeal carcinoma",
author = "Robert, {Mutter W.} and Lok, {Benjamin H.} and Dutta, {Pinaki R.} and Nadeem Riaz and Jeremy Setton and Berry, {Sean L.} and Anuj Goenka and Zhigang Zhang and Shyam Rao and Wolden, {Suzanne L.} and Lee, {Nancy Y.}",
year = "2013",
month = "7",
day = "9",
doi = "10.1186/1748-717X-8-173",
language = "English (US)",
volume = "8",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Constraining the brachial plexus does not compromise regional control in oropharyngeal carcinoma

AU - Robert, Mutter W.

AU - Lok, Benjamin H.

AU - Dutta, Pinaki R.

AU - Riaz, Nadeem

AU - Setton, Jeremy

AU - Berry, Sean L.

AU - Goenka, Anuj

AU - Zhang, Zhigang

AU - Rao, Shyam

AU - Wolden, Suzanne L.

AU - Lee, Nancy Y.

PY - 2013/7/9

Y1 - 2013/7/9

N2 - Background: Accumulating evidence suggests that brachial plexopathy following head and neck cancer radiotherapy may be underreported and that this toxicity is associated with a dose-response. Our purpose was to determine whether the dose to the brachial plexus (BP) can be constrained, without compromising regional control.Methods: The radiation plans of 324 patients with oropharyngeal carcinoma (OPC) treated with intensity-modulated radiation therapy (IMRT) were reviewed. We identified 42 patients (13%) with gross nodal disease <1 cm from the BP. Normal tissue constraints included a maximum dose of 66 Gy and a D05 of 60 Gy for the BP. These criteria took precedence over planning target volume (PTV) coverage of nodal disease near the BP.Results: There was only one regional failure in the vicinity of the BP, salvaged with neck dissection (ND) and regional re-irradiation. There have been no reported episodes of brachial plexopathy to date.Conclusions: In combined-modality therapy, including ND as salvage, regional control did not appear to be compromised by constraining the dose to the BP. This approach may improve the therapeutic ratio by reducing the long-term risk of brachial plexopathy.

AB - Background: Accumulating evidence suggests that brachial plexopathy following head and neck cancer radiotherapy may be underreported and that this toxicity is associated with a dose-response. Our purpose was to determine whether the dose to the brachial plexus (BP) can be constrained, without compromising regional control.Methods: The radiation plans of 324 patients with oropharyngeal carcinoma (OPC) treated with intensity-modulated radiation therapy (IMRT) were reviewed. We identified 42 patients (13%) with gross nodal disease <1 cm from the BP. Normal tissue constraints included a maximum dose of 66 Gy and a D05 of 60 Gy for the BP. These criteria took precedence over planning target volume (PTV) coverage of nodal disease near the BP.Results: There was only one regional failure in the vicinity of the BP, salvaged with neck dissection (ND) and regional re-irradiation. There have been no reported episodes of brachial plexopathy to date.Conclusions: In combined-modality therapy, including ND as salvage, regional control did not appear to be compromised by constraining the dose to the BP. This approach may improve the therapeutic ratio by reducing the long-term risk of brachial plexopathy.

KW - Brachial plexopathy

KW - Cetuximab

KW - Cisplatin

KW - Intensity-modulated radiation therapy

KW - Oropharyngeal carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84880024954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880024954&partnerID=8YFLogxK

U2 - 10.1186/1748-717X-8-173

DO - 10.1186/1748-717X-8-173

M3 - Article

C2 - 23835205

AN - SCOPUS:84880024954

VL - 8

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 173

ER -